Abstract:Background: Chiglitazar is a novel PPARα/γ/δ pan-agonist with moderate transcriptional activities. Phase 2 studies demonstrated that chiglitazar had significant effects on glycemic control and lipid modulation in patients with type 2 diabetes. The current CMAP study aimed to assess the efficacy and safety of chiglitazar compared with placebo in type 2 diabetes patients who had not previously received anti-diabetic treatment.Methods: This study was a double-blind and placebo-controlled phase 3 trial conducted at 26 centres in China. Eligible patients were 18-70 years old, type 2 diabetes with HbA1c ≥7*5% and ≤10*0% and without previous anti-diabetic treatment. Patients were randomly assigned to receive chiglitazar 32 mg or 48 mg, or placebo once daily. The primary endpoint was change in HbA1c at week 24 with superiority of chiglitazar to placebo.Findings: Between June 17, 2014, and Oct 13, 2016, 535 patients were randomly assigned to receive chiglitazar 32 mg (n=167), 48 mg (n=166), or placebo (n=202). In the primary LOCF analysis in the full-analysispopulation, both chiglitazar doses were superior to placebo for HbA1c reduction at week 24, with the mean differences between chiglitazar 32 mg or 48 mg versus placebo were -0*87% [95% CI -1*10 to -0*65] or -1*05% [- 1*29 to -0*81], respectively. Overall frequency of adverse events and study discontinuation attributable to adverse events were similar among groups. Serious adverse events were reported for seven (3%) in the placebo group, four (2%) in the chiglitazar 32 mg group, and eight (5%) in the chiglitazar 48 mg group. A small increased mild edema events and body weight gain was reported in the chiglitazar dose groups.Interpretation: The PPAR pan-agonist chiglitazar had significant and clinically relevant improvements in glycaemic control in patients with type 2 diabetes, with no unexpected safety findings.Trial Registration: This study is registered with clinicaltrials.gov number NCT02121717.Funding Statement: Chipscreen Biosciences. This study was partly supported by grants from Chinese National and Provincial Major Project for New Drug Innovation (National: 2008ZX09101-002, 2013ZX09401301; Provincial: 2011A080501010) and Shenzhen Municipal Major Project (2010-1746). Declaration of Interests: ZN, HC, DP, HY and XL are employees of Chipscreen Biosciences Ltd. The other authors declare no competing interests.Ethics Approval Statement: The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by institutional review boards and independent ethics committees for participating centers. All participants provided written informed consent.

Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)

18-OR: Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)

Efficacy and Safety of Chiglitazar in Type 2 Diabetes:A Multi?center, Randomized, Double?blind, and Parallel Group Clinical Trial

Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials

Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes

Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study

In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist

Personalized Glucose-Lowering Effect of Chiglitazar in Type 2 Diabetes

841-P: Phenomapping-Derived Tool to Personalize Chiglitazar Treatment in Type 2 Diabetes—A Post Hoc Analysis of Randomised Clinical Trials

Chiglitazar Preferentially Regulates Gene Expression Via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ

[Efficacy and Safety of Alogliptin in Treatment of Type 2 Diabetes Mellitus: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial in Mainland China].

Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects.

Efficacy and Safety of Alogliptin in Patients with Type 2 Diabetes Mellitus: A Multicentre Randomized Double‐blind Placebo‐controlled Phase 3 Study in Mainland China, Taiwan, and Hong Kong

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: an Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers

[The Efficacy and Safety of Pioglitazone Hydrochloride in Combination with Sulphonylureas and Metfomin in the Treatment of Type 2 Diabetes Mellitus a 12-Week Randomized Multi-Centres Placebo-Controlled Parallel Study].

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin